New study aims to make vital malaria drug safer for millions
NCT ID NCT07468513
Summary
This study is testing the safety and effectiveness of a malaria drug called primaquine in people who have a common enzyme deficiency called G6PD. It will enroll 100 adults with a specific type of malaria. The goal is to find safer dosing schedules so this important drug can be used more widely to control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VIVAX MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arba Minch General Hospital
NOT_YET_RECRUITINGArba Minch, Ethiopia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dr Marcus Lacerda
RECRUITINGManaus, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dr Moses Laman and Dr Brioni Moore
RECRUITINGAlexishafen, Madang Province, Papua New Guinea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Papua New Guinea Institute of Medical Research
RECRUITINGPort Moresby, Magang, Papua New Guinea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.